Neuroscience research continues to evolve in order to cope up with changing industry dynamics. Recent strategic partnerships and mergers have not only experienced R&D cuts but also shut down of entire R&D sites. As a result, industry is now more keen on investing in biotechnology start-ups to build their new pipeline for neuro products.
Discovering medicines to treat neurodegenerative disorders like Alzheimer’s, Parkinson’s and Dementia has been extremely challenging in the past decades. But through recent advances in stem cell technology, functional neuroimaging, better animal models, neuromodulation and deep brain stimulation; scientific understanding and expectations are now gathering pace.
The 4th Annual Neuroscience R&D Technologies Conference” being held on 4th-5thOctober in Munich, Germany will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims bringing in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries. There would be live case studies, keynote presentations and breakthrough panel discussion sessions during the two-day meet.